Seeking Alpha · Mar 19, 2024
Strike While The Market Is Hot
Companies are taking advantage of strong investor demand in the investment grade credit market.
KR
NASDAQ · KRTX
Karuna Therapeutics, Inc.
Healthcare · Biotechnology
$329.83
Up+$0.09 (+0.03%)
Updated Sep 11, 2026, 11:01 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 12.6B
- P/E ratio
- -28.11
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 1.28M
- Avg. volume
- 816.4K
Price performance
KRTX price history
1M range · 0 trading sessions · Daily adjusted prices
KRTX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest KRTX news
The latest Smart Investors Daily articles mentioning KRTX.
Stock researchCompany · Overview
KRTX research
Overview
Company profile and research snapshot.
Company profile
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $257.50
- Implied upside
- —
- Analysts
- 23
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 14, 2024 | HC Wainwright & Co. | Neutral | — |
| Mar 11, 2024 | HC Wainwright & Co. | Neutral | — |
| Feb 20, 2024 | Cantor Fitzgerald | Neutral | — |
| Jan 26, 2024 | Mizuho | Neutral | — |
| Jan 17, 2024 | Cantor Fitzgerald | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 27, 2024
Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect
Hedge funds are steering clear of the booming artificial intelligence (AI) market and other technology stocks that have led the market rally over the past year. Instead, they are placing their bets on the healthcare sector, revealing a calculated move towards stability and value. According to the Goldman Sachs Hedge Funds Monitor, hedge funds are heavily favoring the healthcare sector, allocating to it over 600 basis points beyond the benchmark’s weight. In the S&P 500, the healthcare sector boasts a 12.8% weight, while tech nearly 30%. For the median hedge fund portfolio as of the end of ...Full story available on Benzinga.com
Zacks Investment Research · Feb 23, 2024
Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout
Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.
Seeking Alpha · Feb 17, 2024
Asset Class And Stock Performance Since 10/27/23
Since October 27th (less than four months ago), the S&P 500 ETF (SPY) is now up 22.8%. That's a big move.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
